Drug Search Results
More Filters [+]

GSK-2336805

Alternative Names: gsk-2336805, gsk2336805, gsk 2336805, gsk-2236805, gsk2236805, gsk 2236805
Latest Update: 2017-12-11
Latest Update Note: Clinical Trial Update

Product Description

GSK2336805 is a hepatitis C virus (HCV) NS5A inhibitor being developed for the treatment of chronic hepatitis C (CHC). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01439373)

Mechanisms of Action: HCV-NS5A Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-2336805

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatitis C, Chronic|Hepatitis A|Hepatitis C

Phase 1: Hepatitis C|Healthy Volunteers|Hepatitis A

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2012-002555-42

P2

Completed

Hepatitis C, Chronic

2016-01-25

2012-000523-40

P2

Completed

Hepatitis C

2014-09-11

HAI115879

P2

Completed

Hepatitis A|Hepatitis C, Chronic

2014-07-01

HAI117380

P1

Completed

Hepatitis C

2014-03-20

Recent News Events

Date

Type

Title